Introduction: In recent years, targeted therapeutic options for metastatic breast cancer (mBC) have improved significantly. In this analysis, we evaluated overall survival (OS) data of a prospectively documented cohort of 1000 patients with mBC treated at the NCT Heidelberg from 2014 to 2022. Patients and methods: Clinical data were prospectively collected and documented in the Prospective Academic Translational Research PRAEGNANT Network. OS was analyzed according to molecular subtype and line of therapy at study entry. We further evaluated the clinical characteristics associated with long-term (>5 years) and short-term (5 years) were more frequently ER-, PR-, and HER2-positive, received less often (neo)adjuvant chemotherapy, and had a longer disease-free interval. Conclusion: This prospective real-world analysis of 1000 mBC patients demonstrated significant OS differences, emphasizing the importance of personalized treatment approaches.
Michel et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: